The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain
Open accessAbstract
BACKGROUND: There is a clear need to develop an objective diagnostic test for Alzheimer disease (AD). Changes in the levels of cerebrospinal fluid (CSF) tau protein and beta-amyloid 42 (Abeta42) peptide in patients with AD have been well documented, but the relationship between these biomarkers and neuropathologic changes in the brain is not established. OBJECTIVE: To study the relationship between antemortem CSF biomarker levels and Alzheimer-type neuropathologic changes in the brain. DESIGN: Cross-sectional study to correlate levels of CSF Abeta42, total tau, and phosphorylated tau protein with neuropathologic changes in the brain. SETTING: Academic research. Patients The study included 123 patients (79 with clinically diagnosed AD, 29 with other dementia, and 15 with other neurologic disease). All underwent clinical evaluation and provided antemortem lumbar CSF samples, and neuropathologic data were collected from September 11, 1990, to March 13, 2003, in the Department of Neuroscience and Neurology, University of Kuopio, Kuopio, Finland. MAIN OUTCOME MEASURES: Levels of CSF Abeta42, total tau, and phosphorylated tau protein were measured using standard commercial immunoassays. Neuropathologic evaluations included the classic silver impregnation method and immunohistochemistry for Abeta, hyperphosphorylated tau, and alpha-synuclein. RESULTS: Cerebrospinal fluid Abeta42 and tau protein levels were related to amyloid load and the presence of neurofibrillary pathologic abnormalities in the brain. Cerebrospinal fluid Abeta42 level correlated inversely with total Abeta load in the brain, and CSF tau level correlated with results of immunohistochemistry for hyperphosphorylated tau and with the presence of neocortical neurofibrillary tangles. In multivariate logistic regression analysis, the number of neuritic plaques in the brain remained a significant predictor of decreased CSF Abeta42 level and of increased CSF tau level. Based on the ratio of phosphorylated tau level to Abeta42 level, sensitivity was 91.6%, and specificity was 85.7%, with an overall accuracy of 90.2% for the presence of pathologic neuritic plaque in the brain. CONCLUSIONS: Cerebrospinal fluid Abeta42 and tau proteins are biomarkers of AD-associated pathologic changes in the brain. The combination of abnormally low CSF Abeta42 level and abnormally high CSF tau level predicted the presence of AD pathologic features with high accuracy. This combination assay may be helpful in diagnosing the presence of AD pathologic changes in the brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A characteristic biomarker profile, defined by reduced levels of Aβ42 in conjunction with elevated t-tau and p-tau, provides a robust biochemical signature for detecting AD pathology and distinguishing it from other neurodegenerative disorders72,73.”
From Artificial intelligence-driven multi-omics approaches in Alzheimer's disease: Progress, challenges, and future directions (2025) · cites this paper as [73]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Given that a CSF Aβ42 concentration lower than 500 pg/mL has been utilized as a reliable threshold for the presence of cerebral Aβ deposition in humans (7, 19, 22, 26)”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [26]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The level of CSF P-tau also does correlate with severity of PHF tau accumulation after death [81,150].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [150]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D. L., & Stadlan, E. (2011) · Neurology · doi:10.1212/01.wnl.0000400650.92875.cf · Cited by 9,882
Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
McKeith, I. G., Dickson, D. W., Lowe, J., Emre, M., O'Brien, J. T., Feldman, H., Cummings, J., Duda, J. E., Lippa, C., Perry, E. K., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000187889.17253.b1 · Cited by 5,069
Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
Neary, D., Snowden, J. S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., Robert, P. H., Albert, M., et al. (1998) · Neurology · doi:10.1212/wnl.51.6.1546 · Cited by 5,047
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172
Self-citationHansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700
Cited by
Sorted by citations
Items 201–300 of 895
Formaglio, M., Costes, N., Seguin, J., Tholance, Y., Bars, D. L., Roullet‐Solignac, I., Mercier, B., Krolak‐Salmon, P., & Vighetto, A. (2011) · Journal of Neurology · doi:10.1007/s00415-011-6030-0 · Cited by 72
Early diagnosis of Alzheimer's disease from elevated olfactory mucosal miR-206 level.
Moon, J., Lee, S.-T., Kong, I. G., Byun, J.-I., Sunwoo, J.-S., Shin, J.-W., Shim, J.-Y., Park, J.-H., Jeon, D., Jung, K.-H., et al. (2016) · Scientific Reports · doi:10.1038/srep20364 · Cited by 69
Lebouvier, T., Pasquier, F., & Buée, L. (2017) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000502 · Cited by 77
d’Abramo, C., D'adamio, L., & Giliberto, L. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030116 · Cited by 71
Hendrickson, R. C., Lee, A. Y. H., Song, Q., Liaw, A. I., Wiener, M., Paweletz, C. P., Seeburger, J. L., Li, J., Meng, F., Deyanova, E. G., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135365 · Cited by 68
CSF Biomarkers for Amyloid and Tau Pathology in Alzheimer's Disease
Rosenmann, H. (2011) · Journal of Molecular Neuroscience · doi:10.1007/s12031-011-9665-5 · Cited by 72
Ebadi, A., da Rocha, J. L. D., Nagaraju, D. B., Tovar-Moll, F. F., Bramati, I. E., Coutinho, G., Sitaram, R., & Rashidi, P. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00056 · Cited by 71
Guo, Y., Liu, F., Hou, X., Li, J., Cao, X., Tan, L., Wang, J., & Yu, J. (2020) · Journal of Neurology · doi:10.1007/s00415-020-09757-9 · Cited by 68
Irwin, D. J., Lleó, A., Xie, S. X., McMillan, C. T., Wolk, D. A., Lee, E. B., Van Deerlin, V. M., Shaw, L. M., Trojanowski, J. Q., & Grossman, M. (2017) · Annals of Neurology · doi:10.1002/ana.24996 · Cited by 67
Mouton‐Liger, F., Wallon, D., Troussière, A., Yatimi, R., Dumurgier, J., Magnin, É., Sayette, V. D. L., Duron, E., Philippi, N., Beaufils, É., et al. (2013) · Journal of Neurology · doi:10.1007/s00415-013-7160-3 · Cited by 67
Criscuolo, C., Fabiani, C., Bonadonna, C., Origlia, N., & Domenici, L. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.11.016 · Cited by 67
A deep learning MRI approach outperforms other biomarkers of prodromal Alzheimer’s disease
Feng, X., Provenzano, F. A., Small, S. A., & Initiative, A. D. N. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-00985-x · Cited by 68
Alzheimer’s disease biomarkers and their current use in clinical research and practice
Hunter, T., Santos, L. E., Tovar-Moll, F. F., & Felice, F. G. D. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02709-z · Cited by 78
Deep learning for clustering of multivariate clinical patient trajectories with missing values
de Jong, J., Emon, M. A., Wu, P., Karki, R., Sood, M., Godard, P., Ahmad, A., Vrooman, H. A., Hofmann‐Apitius, M., & Fröhlich, H. (2019) · GigaScience · doi:10.1093/gigascience/giz134 · Cited by 69
Luo, X., Hou, L., Shi, H., Zhong, X., Zhang, Y., Zheng, D., Tan, Y., Guoyan, H., Mu, N., Chan, J., et al. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12331 · Cited by 66
CSF p-Tau levels in the prediction of Alzheimer's disease
Kandimalla, R. J. L., Prabhakar, S. K., Wani, W. Y., Kaushal, A., Gupta, N., Sharma, D. R., Grover, V., Bhardwaj, N., Jain, K., & Gill, K. D. (2013) · Biology Open · doi:10.1242/bio.20135447 · Cited by 68
Ultra-sensitive detection of protein biomarkers for diagnosis of Alzheimer’s disease
Chan, H., Xu, D., Ho, S., Wong, M. S., & Li, H. (2017) · Chemical Science · doi:10.1039/c6sc05615f · Cited by 65
Clinical and research diagnostic criteria for Alzheimer's disease
Sarazin, M., de Souza, L. C., Lehéricy, S., & Dubois, B. (2012) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2011.11.004 · Cited by 64
Arginine vasopressin in cerebrospinal fluid is a marker of sociality in nonhuman primates
Parker, K. J., Garner, J. P., Oztan, O., Tarara, E. R., Li, J., Sclafani, V., Del Rosso, L. A., Chun, K., Berquist, S. W., Chez, M. G., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aam9100 · Cited by 64
Mouton‐Liger, F., Paquet, C., Dumurgier, J., Lapalus, P., Gray, F., Laplanche, J., & Hugon, J. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.11.031 · Cited by 67
Wang, Y., Chen, J., Du, Z., Weng, H., Zhang, Y., Li, R., Jia, Z., Sun, M., Jiang, J., Wang, F.-Z., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.695696 · Cited by 64
Nu, T. T. V., Tran, N. H. T., Nam, E., Nguyen, T. T., Yoon, W. J., Cho, S., Kim, J., Chang, K.-A., & Ju, H. (2018) · RSC Advances · doi:10.1039/c7ra11637c · Cited by 63
Challenges associated with biomarker‐based classification systems for Alzheimer's disease
Illán‐Gala, I., Pegueroles, J., Montal, V., Vilaplana, E., Carmona‐Iragui, M., Alcolea, D., Dickerson, B. C., Sánchez‐Valle, R., de Leon, M. J., Blesa, R., et al. (2018) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.03.004 · Cited by 62
Luk, C. Y., Compta, Y., Magdalinou, N. K., Martı́, M. J., Hondhamuni, G., Zetterberg, H., Blennow, K., Constantinescu, R., Pijnenburg, Y. A. L., Mollenhauer, B., et al. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07911.x · Cited by 65
Gold Nanoparticles as a Probe for Amyloid-β Oligomer and Amyloid Formation
Elbassal, E. A., Morris, C., Kent, T. W., Lantz, R., Ojha, B., Wojcikiewicz, E. P., & Du, D. (2017) · The Journal of Physical Chemistry C · doi:10.1021/acs.jpcc.7b05169 · Cited by 62
Primary Progressive Aphasia in the Network of French Alzheimer Plan Memory Centers
Magnin, É., Démonet, J., Wallon, D., Dumurgier, J., Troussière, A., Jager, A., Duron, E., Gabelle, A., Sayette, V. D. L., Volpe‐Gillot, L., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160536 · Cited by 61
Development and validation of a high‐sensitivity assay for measuring p217+tau in plasma
Triana‐Baltzer, G., Moughadam, S., Slemmon, R., Kolen, K. V., Theunis, C., Mercken, M. H., & Kolb, H. C. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12204 · Cited by 63
Predicting the course of Alzheimer’s progression
Initiative, A. D. N., Iddi, S., Li, D., Aisen, P. S. S., Rafii, M. S., Thompson, W. K., & Donohue, M. (2019) · Brain Informatics · doi:10.1186/s40708-019-0099-0 · Cited by 64
Gabelle, A., Dumurgier, J., Vercruysse, O., Paquet, C., Bombois, S., Laplanche, J., Peoc’h, K., Schraen‐Maschke, S., Buée, L., Pasquier, F., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121549 · Cited by 60
Unbiased Approaches to Biomarker Discovery in Neurodegenerative Diseases
Chen‐Plotkin, A. S. (2014) · Neuron · doi:10.1016/j.neuron.2014.10.031 · Cited by 62
Yang, S. J., Lee, J. U., Jeon, M. J., & Sim, S. J. (2022) · Analytica Chimica Acta · doi:10.1016/j.aca.2022.339445 · Cited by 59
Sauvée, M., Didierlaurent, G., Latarche, C., Escanyé, M., Olivier, J. L., & Malaplate, C. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131838 · Cited by 58
Integrating ADNI results into Alzheimer's disease drug development programs
Cummings, J. L. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.03.016 · Cited by 59
Malishkevich, A., Marshall, G. A., Schultz, A. P., Sperling, R. A., Aharon‐Peretz, J., & Gozes, I. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150799 · Cited by 58
Preclinical Amyloid-β and Axonal Degeneration Pathology in Delirium
Idland, A., Wyller, T. B., Støen, R., Eri, L. M., Frihagen, F., Raeder, J. C., Chaudhry, F. A., Hansson, O., Zetterberg, H., Blennow, K., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160461 · Cited by 58
Fink, H. A., Linskens, E. J., Silverman, P. C., McCarten, J. R., Hemmy, L. S., Ouellette, J. M., Greer, N. L., Wilt, T. J., & Butler, M. (2020) · Annals of Internal Medicine · doi:10.7326/m19-3888 · Cited by 57
Öhrfelt, A., Johansson, P., Wallin, A., Andréasson, U., Zetterberg, H., Blennow, K., & Svensson, J. (2016) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000447239 · Cited by 59
Bjerke, M., Andréasson, U., Kuhlmann, J., Portelius, E., Pannee, J., Lewczuk, P., Umek, R. M., Vanmechelen, E., Vanderstichele, H., Stoops, E., et al. (2015) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-0733 · Cited by 56
Gul, S. S., Huesgen, K. W., Wang, K., Mark, K., & Tyndall, J. A. (2017) · Medical Hypotheses · doi:10.1016/j.mehy.2017.06.016 · Cited by 56
Sleep spindle abnormalities related to Alzheimer's disease: a systematic mini-review
Weng, Y.-Y., Lei, X., & Yu, J. (2020) · Sleep Medicine · doi:10.1016/j.sleep.2020.07.044 · Cited by 62
Bastard, N. L., Coart, E., Vanderstichele, H., Vanmechelen, E., Martin, J., & Engelborghs, S. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121246 · Cited by 55
El‐Obeid, A., Laurell, K., Cesarini, K. G., & Alafuzoff, I. I. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000191 · Cited by 56
Self-citationA diagnostic scale for Alzheimer’s disease based on cerebrospinal fluid biomarker profiles
Lehmann, S., Dumurgier, J., Schraen‐Maschke, S., Wallon, D., Blanc, F., Magnin, É., Bombois, S., Bousiges, O., Campion, D., Cretin, B., et al. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt267 · Cited by 55
Li, X., Li, T., Andreasen, N. C., Wiberg, M. K., Westman, E., & Wahlund, L. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12164 · Cited by 58
Ding, M., Ding, S., Du, D., Wang, X., Hu, X., Guan, P., Lyu, Z., & Lin, Y. (2023) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2023.117087 · Cited by 56
Maftei, M., Thurm, F., Schnack, C., Tumani, H., Otto, M., Elbert, T. R., Kolassa, I., Przybylski, M., Manea, M., & Arnim, C. A. F. V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068996 · Cited by 54
Gurevich, P., Stuke, H., Kastrup, A., Stuke, H., & Hildebrandt, H. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00114 · Cited by 53
Increased CSF Aβ during the very early phase of cerebral Aβ deposition in mouse models
Maia, L. F., Kaeser, S. A., Reichwald, J., Lambert, M., Obermüller, U., Schelle, J., Odenthal, J., Martus, P., Staufenbiel, M., & Jucker, M. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201505026 · Cited by 55
Baiardi, S., Abu‐Rumeileh, S., Rossi, M., Zenesini, C., Bartoletti‐Stella, A., Polischi, B., Capellari, S., & Parchi, P. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.697 · Cited by 53
Herskovits, A. Z., & Growdon, J. H. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.151 · Cited by 53
Bekris, L. M., Galloway, N. M., Millard, S. P., Lockhart, D., Li, G., Galasko, D. R., Farlow, M. R., Clark, C. M., Quinn, J. F., Kaye, J. A., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.10.020 · Cited by 53
Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies
van Steenoven, I., van der Flier, W. M., Scheltens, P., Teunissen, C. E., & Lemstra, A. W. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0537-5 · Cited by 52
Marshall, G. A., Initiative, A. D. N., Lorius, N., Locascio, J. J., Hyman, B. T., Rentz, D. M., Johnson, K. A., & Sperling, R. A. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132768 · Cited by 52
Grau‐Rivera, O., Gelpí, E., Nos, C., Gaig, C., Ferrer, I., Saiz, A., Lladó, A., Molinuevo, J. L., Graus, F., Sánchez‐Valle, R., et al. (2015) · Neurodegenerative Diseases · doi:10.1159/000439251 · Cited by 51
Antonell, A., Fortea, J., Rami, L., Bosch, B., Balasa, M., Sánchez‐Valle, R., Iranzo, Á., Molinuevo, J. L., & Lladó, A. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0534-0 · Cited by 51
Ye, B. S., Lee, W., Ham, J. H., Lee, J. J., Lee, P. H., Sohn, Y. H., & Initiative, T. A. D. N. (2016) · European Journal of Neurology · doi:10.1111/ene.12969 · Cited by 51
Magalhães, T. N. C., Weiler, M., Teixeira, C. V. L., Hayata, T., Moraes, A. S., Boldrini, V. D. O., dos Santos, L. M., de Campos, B. M., de Rezende, T. J. R., Joaquim, H. P. G., et al. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0795-9 · Cited by 51
Retinal nerve fiber layer thickness predicts CSF amyloid/tau before cognitive decline
Asanad, S., Fantini, M., Sultan, W., Nassisi, M., Felix, C. M., Wu, J., Karanjia, R., Ross‐Cisneros, F. N., Sagare, A. P., Zloković, B. V., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0232785 · Cited by 55
Chen, J., Fears, S. C., Jasinska, A. J., Huang, A., Al‐Sharif, N., Scheibel, K. E., Dyer, T. D., Fagan, A. M., Blangero, J., Woods, R. P., et al. (2018) · Brain and Behavior · doi:10.1002/brb3.903 · Cited by 52
APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer’s disease
Konijnenberg, E., Tijms, B. M., Gobom, J., Dobričić, V., Bos, I., Vos, S. J. B., Tsolaki, M., Verhey, F. R. J., Popp, J., Martínez‐Lage, P., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00628-z · Cited by 50
Asanad, S., Felix, C. M., Fantini, M., Harrington, M. G., Sadun, A. A., & Karanjia, R. (2021) · Scientific Reports · doi:10.1038/s41598-021-85010-1 · Cited by 49
Kang, K., Ko, P., Jin, M., Suk, K., & Lee, H. (2014) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2013.11.039 · Cited by 49
Mathew, B., Mansuri, M. S., Williams, K. R., & Nairn, A. C. (2021) · Brain Sciences · doi:10.3390/brainsci11020258 · Cited by 50
Dkk‐3 is elevated in CSF and plasma of Alzheimer’s disease patients
Zenzmaier, C., Marksteiner, J., Kiefer, A., Berger, P., & Humpel, C. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06158.x · Cited by 49
Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease
Mattsson, N., Zetterberg, H., & Blennow, K. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2010/610613 · Cited by 50
Plasma Tau Levels in Cognitively Normal Middle-Aged and Older Adults
Chiu, M., Fan, L., Chen, T., Chen, Y., Chieh, J.-J., & Horng, H. E. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00051 · Cited by 48
Hosaka, T., Yamashita, T., Tamaoka, A., & Kwak, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133148 · Cited by 49
Ruthirakuhan, M. T., Herrmann, N., Andreazza, A. C., Verhoeff, N. P. L. G., Gallagher, D., Black, S. E., Kiss, A., & Lanctôt, K. L. (2019) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988719874118 · Cited by 48
Tripoliti, E. E., Fotiadis, D. I., & Argyropoulou, M. I. (2011) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2011.05.005 · Cited by 49
Ramcharitar, J., Albrecht, S., Afonso, V. M., Kaushal, V., Bennett, D. A., & LeBlanc, A. C. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3182a0a39f · Cited by 47
Sánchez-Tapia, M., Mimenza-Alvarado, A., Granados-Domínguez, L., Flores-López, A., López-Barradas, A., Ortiz, V., Pérez-Cruz, C., Sánchez-Vidal, H., Hernández-Acosta, J., Ávila-Funes, J. A., et al. (2023) · Nutrients · doi:10.3390/nu15040932 · Cited by 47
Martínez-Dubarbie, F., Guerra-Ruiz, A., López-García, S., Lage, C., Fernández-Matarrubia, M., Infante, J., Pozueta-Cantudo, A., García-Martínez, M., Corrales-Pardo, A., Bravo, M., et al. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01319-1 · Cited by 47
Alzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers
Thal, D. R., Poesen, K., Vandenberghe, R. R., & Meyer, S. D. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00819-y · Cited by 55
Thakur, K., Zhu, Y.-Y., Feng, J., Zhang, J., Hu, F., Prasad, C., & Wei, Z. (2020) · Food & Function · doi:10.1039/d0fo01444c · Cited by 47
Turk, K. W., Geada, A., Alvarez, V. E., Xia, W., Cherry, J. D., Nicks, R., Meng, G., Daley, S. A., Tripodis, Y., Huber, B. R., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-00976-y · Cited by 47
Mitochondrial DNA and Exercise: Implications for Health and Injuries in Sports
Zanini, G., De Gaetano, A., Selleri, V., Savino, G., Cossarizza, A., Pinti, M., Mattioli, A. V., & Nasi, M. (2021) · Cells · doi:10.3390/cells10102575 · Cited by 46
Tariciotti, L., Casadei, M., Honig, L. S., Teich, A. F., McKhann, G. M., Tosto, G., & Mayeux, R. P. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180548 · Cited by 46
Leung, Y. Y., Toledo, J. B., Nefedov, A., Robi Polikar, A., Raghavan, N., Xie, S. X., Farnum, M. A., Schultz, T., Baek, Y., Deerlin, V. M. V., et al. (2015) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.06.008 · Cited by 49
Visual ratings of atrophy in MCI: prediction of conversion and relationship with CSF biomarkers
Lehmann, M., Koedam, E., Barnes, J., Bartlett, J. W., Barkhof, F., Wattjes, M. P., Schott, J. M., Scheltens, P., & Fox, N. C. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.03.010 · Cited by 49
Gervaise-Henry, C., Watfa, G., Albuisson, É., Kolodziej, A., Dousset, B., Olivier, J. L., Jonveaux, T., & Malaplate, C. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160865 · Cited by 46
Blennow, K., & Zetterberg, H. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.07.006 · Cited by 46
Ganglion cell layer thinning in prodromal Alzheimer's disease defined by amyloid PET
López‐de‐Eguileta, A., Lage, C., López‐García, S., Pozueta, A., García‐Martínez, M., Kazimierczak, M., Bravo, M., de Arcocha-Torres, M., Banzo, I., Jiménez-Bonilla, J. F., et al. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.08.008 · Cited by 46
Blood Biomarkers for Alzheimer’s Disease in Down Syndrome
Montoliu‐Gaya, L., Strydom, A., Blennow, K., Zetterberg, H., & Ashton, N. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10163639 · Cited by 46
Song, L., Qu, Y. Q., Tang, Y. P., Chen, X., Lo, H. H., Li, Q., Yun, Y. X., Wong, V. K. W., Zhang, R. L., Wang, H. M., et al. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102637 · Cited by 45
Vitamin D basis of Alzheimer’s disease: from genetics to biomarkers
Dursun, E., & Gezen‐Ak, D. (2018) · HORMONES · doi:10.1007/s42000-018-0086-5 · Cited by 45
Alzheimer CSF biomarkers in routine clinical setting
Tabaraud, F., Leman, J. P., Milor, A.-M., Roussie, J. M., Barrière, G., Tartary, M., Boutros-Toni, F., & Rigaud, M. (2011) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2011.01592.x · Cited by 44
Dumurgier, J., Paquet, C., Benisty, S., Kiffel, C., Lidy, C., Mouton‐Liger, F., Chabriat, H., Laplanche, J., & Hugon, J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.07.007 · Cited by 44
TDP ‐43 in amyotrophic lateral sclerosis – is it a prion disease?
Ludolph, A. C., & Brettschneider, J. (2015) · European Journal of Neurology · doi:10.1111/ene.12706 · Cited by 45
Defining and predicting transdiagnostic categories of neurodegenerative disease
Cornblath, E. J., Robinson, J. L., Irwin, D. J., Lee, E. B., Lee, V. M. ‐., Trojanowski, J. Q., & Bassett, D. S. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-0593-y · Cited by 48
Polis, B., & Samson, A. O. (2024) · Journal of Alzheimer's Disease · doi:10.3233/jad-240058 · Cited by 43
LRRK2 Promotes Tau Accumulation, Aggregation and Release
Guerreiro, P. S., Gerhardt, E., da Fonseca, T. L., Bähr, M., Outeiro, T. F., & Eckermann, K. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9209-z · Cited by 46
A Candidate Plasma Protein Classifier to Identify Alzheimer's Disease
Zhao, X., Lejnine, S., Spond, J., Zhang, C., Ramaraj, T. C., Holder, D., Dai, H. A., WEINER, R. S., & Laterza, O. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-141149 · Cited by 43
Chiu, M., Horng, H. E., Chieh, J.-J., Liao, S. H., Chen, C. H., Shih, B.-Y., Yang, C. C. C.-C., Lee, C. L., Chen, T., Yang, S., et al. (2010) · IEEE Transactions on Applied Superconductivity · doi:10.1109/tasc.2010.2087304 · Cited by 42
Percy, A. J., Yang, J., Chambers, A. G., Simon, R., Hardie, D. B., & Borchers, C. H. (2014) · Journal of Proteome Research · doi:10.1021/pr500317d · Cited by 42
Adenosine receptor signalling in Alzheimer’s disease
Trinh, P. N. H., Baltos, J., Hellyer, S. D., May, L. T., & Gregory, K. J. (2022) · Purinergic Signalling · doi:10.1007/s11302-022-09883-1 · Cited by 43
Fluid and Biopsy Based Biomarkers in Parkinson's Disease
Coughlin, D. G., & Irwin, D. J. (2023) · Neurotherapeutics · doi:10.1007/s13311-023-01379-z · Cited by 44
Ratio of Aβ42/P-tau181p in CSF is associated with aberrant default mode network in AD
Li, X., Li, T., Andreasen, N., Wiberg, M. K., Westman, E., & Wahlund, L. (2013) · Scientific Reports · doi:10.1038/srep01339 · Cited by 42
Bastard, N. L., Aerts, L., Sleegers, K., Martin, J., Broeckhoven, C. V., Deyn, P. P. D., & Engelborghs, S. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-110029 · Cited by 41
Llorens, F., Schmitz, M., Knipper, T., Schmidt, C., Lange, P., Fischer, A., Hermann, P., & Zerr, I. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00289 · Cited by 41
Cognitive Reserve Relates to Functional Network Efficiency in Alzheimer’s Disease
Weiler, M., Casseb, R. F., de Campos, B. M., Teixeira, C. V. L., Carletti‐Cassani, A. F. M. K., Vicentini, J. E., Magalhães, T. N. C., de Almeira, D. Q., Talib, L. L., Forlenza, O. V., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00255 · Cited by 45
Metadata
- Authors
- Tapiola, T., Alafuzoff, I., Herukka, S.-K., Parkkinen, L., Hartikainen, P., Soininen, H., & Pirttilä, T.
- Affiliations
- University of Eastern Finland (FI)
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2009-03-01
- Volume
- 66
- Issue
- 3
- Pages
- 382-9
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2075193321
- Cited by
- 896
- References
- 29
- Citations by year
- 2026: 18 · 2025: 27 · 2024: 45 · 2023: 27 · 2022: 34 · 2021: 78 · 2020: 89 · 2019: 75 · 2018: 60 · 2017: 59 · 2016: 51 · 2015: 65 · 2014: 48 · 2013: 63 · 2012: 41
- FWCI
- 32.16
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Archives of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Kuopion Yliopistollinen Sairaala
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, cerebrospinal fluid biomarkers, amyloid-beta 42, tau protein, phosphorylated tau, amyloid plaques, neurofibrillary tangles, diagnostic accuracy, lumbar CSF, neurodegeneration, alpha-synuclein, postmortem neuropathology, biomarker ratios, sensitivity and specificity
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Brain, Cross-Sectional Studies, Dementia, Female, Humans, Immunoassay, Male, Nervous System Diseases, Peptide Fragments, Retrospective Studies, ROC Curve, Logistic Models, Amyloid beta-Peptides, Silver Staining, tau Proteins, Statistics, Nonparametric, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
